Other Ventures Segment was HUTCHMED (China)’s largest segment in fiscal 2025, bringing in $261.65M of $362.29M (72%).
| Segment | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Other Ventures Segment | $257.27M | $301.12M | $262.98M | $261.65M | ||||||
| Commercial Platform | — | — | — | — | ||||||
| Oncology/Immunology Segment | $57.06M | $278.86M | $128.01M | $100.64M | ||||||
| Innovation Platform | — | — | — | — | ||||||
| Total | $314.33M | $579.97M | $390.99M | $362.29M |
HUTCHMED (China) brought in $362.29M from its two segments in fiscal 2025, the year ended December 31, 2025. That is less than the $548.51M it reports by geography, so these segments do not cover all of its revenue. Other Ventures Segment was the largest at $261.65M (72.2%), ahead of Oncology/Immunology Segment at $100.64M (27.8%).
Compared with fiscal 2024, Other Ventures Segment fell 0.5% to $261.65M and Oncology/Immunology Segment fell 21.4% to $100.64M.
Prc was HUTCHMED (China)’s largest region in fiscal 2025, bringing in $407.45M of $548.51M (74%).
| Geography | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Prc | $426.41M | $484.90M | $452.41M | $407.45M | ||||||
| United States & Others | — | $353.10M | $177.79M | $141.06M | ||||||
| Hong Kong | — | — | — | — | ||||||
| Total | $426.41M | $838.00M | $630.20M | $548.51M |
HUTCHMED (China) brought in $548.51M from its two regions in fiscal 2025, the year ended December 31, 2025. That was down 13.0% from $630.20M in fiscal 2024. Prc was the largest at $407.45M (74.3%), ahead of United States & Others at $141.06M (25.7%).
Compared with fiscal 2024, Prc fell 9.9% to $407.45M and United States & Others fell 20.7% to $141.06M.
HUTCHMED (China) began breaking out United States & Others in fiscal 2023, when it brought in $353.10M.
Third Parties was HUTCHMED (China)’s largest revenue line in fiscal 2025, bringing in $330.07M of $473.77M (70%).
| Related and Nonrelated Parties | FY 2021 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Third Parties | $579.97M | $433.94M | $330.07M | |
| Customer A | — | — | $141.06M | |
| Customer B | $84.07M | $85.36M | — | |
| Customer C | — | — | — | |
| Customer D | — | — | — | |
| Related Parties | $8.75M | $4.33M | $1.32M | |
| Equity Method Investee | $6.35M | $3.85M | $1.32M | |
| Indirect Subsidiaries Of Ck Hutchison | $1.91M | $5.00K | — | |
| Total | $681.05M | $527.48M | $473.77M |
HUTCHMED (China) brought in $473.77M from its four revenue lines in fiscal 2025, the year ended December 31, 2025. That is less than the $548.51M it reports by geography, so these revenue lines do not cover all of its revenue. Third Parties was the largest at $330.07M (69.7%), ahead of Customer A at $141.06M (29.8%) and Related Parties at $1.32M (0.3%). The remaining revenue line, Equity Method Investee, brought in $1.32M.
HUTCHMED (China) began breaking out Customer A in fiscal 2025, when it brought in $141.06M. HUTCHMED (China) stopped reporting Customer B ($85.36M in fiscal 2024) and Indirect Subsidiaries Of Ck Hutchison ($5.00K in fiscal 2024) as separate revenue lines.
HUTCHMED (China) (HCM) reports its revenue by segment, by geography and by related and nonrelated parties. In fiscal 2025, Other Ventures Segment was its largest segment, bringing in $261.65M (72.2% of the total), followed by Oncology/Immunology Segment at $100.64M (27.8%).
Other Ventures Segment was HUTCHMED (China)'s largest segment in fiscal 2025, bringing in $261.65M, or 72.2% of the $362.29M total across its two segments.
Prc was HUTCHMED (China)'s largest region in fiscal 2025, bringing in $407.45M, or 74.3% of the $548.51M total across its two regions.
Third Parties was HUTCHMED (China)'s largest revenue line in fiscal 2025, bringing in $330.07M, or 69.7% of the $473.77M total across its four revenue lines.
Every figure comes from HUTCHMED (China)'s annual financial filings, as reported. Each line keeps the name HUTCHMED (China) gives it, and years follow its fiscal calendar.
HUTCHMED (China)'s revenue by segment goes back to fiscal 2016, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.